Digitalni repozitorij raziskovalnih organizacij Slovenije

Izpis gradiva
A+ | A- | Pomoč | SLO | ENG

Naslov:Induction chemotherapy, chemoradiotherapy and consolidation chemotherapy in preoperative treatment of rectal cancer : long-term results of phase II OIGIT-01 Trial
Avtorji:ID Golo, Danijela (Avtor)
ID But-Hadžić, Jasna (Avtor)
ID Anderluh, Franc (Avtor)
ID Brecelj, Erik (Avtor)
ID Edhemović, Ibrahim (Avtor)
ID Jeromen, Ana (Avtor)
ID Omejc, Mirko (Avtor)
ID Oblak, Irena (Avtor)
ID Šečerov Ermenc, Ajra (Avtor)
ID Velenik, Vaneja (Avtor)
Datoteke:URL URL - Izvorni URL, za dostop obiščite https://content.sciendo.com/view/journals/raon/52/3/article-p267.xml
 
.pdf PDF - Predstavitvena datoteka, prenos (1,27 MB)
MD5: 9F846E2FCD30FE029C03B1EDDC17A28B
 
Jezik:Angleški jezik
Tipologija:1.01 - Izvirni znanstveni članek
Organizacija:Logo OI - Onkološki inštitut Ljubljana
Povzetek:The purpose of the study was to improve treatment efficacy for locally advanced rectal cancer (LARC) by shifting half of adjuvant chemotherapy preoperatively to one induction and two consolidation cycles. Patients and methods Between October 2011 and April 2013, 66 patients with LARC were treated with one induction chemotherapy cycle followed by chemoradiotherapy (CRT), two consolidation cycles, surgery and three adjuvant capecitabine cycles. Radiation doses were 50.4 Gy for T2-3 and 54 Gy for T4 tumours in 1.8 Gy daily fraction. The doses of concomitant and neo/adjuvant capecitabine were 825 mg/m2/12h and 1250mg/m2/12h, respectively. The primary endpoint was pathologic complete response (pCR). Results Forty-three (65.1%) patients were treated according to protocol. The compliance rates for induction, consolidation, and adjuvant chemotherapy were 98.5%, 93.8% and 87.3%, respectively. CRT was completed by 65/66 patients, with G % 3 non-hematologic toxicity at 13.6%. The rate of pCR (17.5%) was not increased, but N and the total-down staging rates were 77.7% and 79.3%, respectively. In a median follow-up of 55 months, we recorded one local relapse (LR) (1.6%). The 5-year disease-free survival (DFS) and overall survival (OS) rates were 64.0% (95% CI 63.89%64.11) and 69.5% (95% CI 69.39%69.61), respectively. Conclusions In LARC preoperative treatment intensification with capecitabine before and after radiotherapy is well tolerated, with a high compliance rate and acceptable toxicity. Though it does not improve the local effect, it achieves a high LR rate, DFS, and OS.
Ključne besede:rectal cancer, neoadjuvant chemotherapy, preoperative chemoradiotherapy
Status publikacije:Objavljeno
Verzija publikacije:Objavljena publikacija
Datum objave:01.09.2018
Založnik:Association of Radiology and Oncology
Leto izida:2018
Št. strani:str. 267-274, III
Številčenje:Vol. 52, no. 3
Izvor:Ljubljana
PID:20.500.12556/DiRROS-19082 Novo okno
UDK:616.3
ISSN pri članku:1318-2099
COBISS.SI-ID:3025275 Novo okno
Avtorske pravice:by Authors
Datum objave v DiRROS:11.06.2024
Število ogledov:545
Število prenosov:261
Metapodatki:XML DC-XML DC-RDF
:
GOLO, Danijela, BUT-HADŽIĆ, Jasna, ANDERLUH, Franc, BRECELJ, Erik, EDHEMOVIĆ, Ibrahim, JEROMEN, Ana, OMEJC, Mirko, OBLAK, Irena, ŠEČEROV ERMENC, Ajra in VELENIK, Vaneja, 2018, Induction chemotherapy, chemoradiotherapy and consolidation chemotherapy in preoperative treatment of rectal cancer : long-term results of phase II OIGIT-01 Trial. Radiology and oncology [na spletu]. 2018. Vol. 52, no. 3, p. 267–274, iii. [Dostopano 11 april 2025]. Pridobljeno s: https://dirros.openscience.si/IzpisGradiva.php?lang=slv&id=19082
Kopiraj citat
  
Objavi na:Bookmark and Share


Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše podrobnosti ali sproži prenos.

Gradivo je del revije

Naslov:Radiology and oncology
Skrajšan naslov:Radiol. oncol.
Založnik:Slovenian Medical Society - Section of Radiology, Croatian Medical Association - Croatian Society of Radiology
ISSN:1318-2099
COBISS.SI-ID:32649472 Novo okno

Sekundarni jezik

Jezik:Slovenski jezik
Ključne besede:rak danke, neoadjuvantna kemoterapija, predoperativna kemoradioterapija


Nazaj